Both Viberzi and Armodafinil offer similar effectiveness, with differences in speed and duration of relief.

Both drugs have comparable safety profiles, with mild side effects that are generally well-tolerated.

Both drugs are low-risk for addiction when used properly, with minimal potential for misuse.

Both drugs are easy to use, with clear dosing schedules to ensure treatment adherence.

Armodafinil is safer for patients with cardiovascular issues or diabetes.

Both drugs are good options depending on the patient’s needs, with Viberzi better for quick relief and Armodafinil for long-term management.